4.5 Article

Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease

Journal

JAMA NEUROLOGY
Volume 72, Issue 1, Pages 100-105

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jamaneurol.2014.2704

Keywords

-

Funding

  1. Canadian Health Institutes of Research (CIHR) Clinician-Scientist Award
  2. Brain Canada
  3. CIHR
  4. Edmond J. Safra Philanthropic Foundation
  5. Michael J. Fox Foundation (MJFF)
  6. National Parkinson Foundation (NPF)
  7. Parkinson Society Canada (PSC)
  8. Tourette Syndrome Association
  9. W. Garfield Weston Foundation
  10. National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) [P50 NS072187]
  11. Mayo Clinic Center for Regenerative Medicine
  12. MJFF
  13. NIH/NINDS [P50 NS072187, R01 NS078086, P50 NS053488]
  14. NIH (National Institute on Aging [NIA]) [P01 AG 09215-20]
  15. NIA [P30 AG 10124-18, PO1 AG 17586-10, 1PO1 AG-19724-07, 1 U01 AG 024904-05, UO1 AG029213-01, RC2NS069368, RC1AG035427, P30AG036468]
  16. NINDS [P50 NS053488-02]
  17. Marian S. Ware Alzheimer Program
  18. NIH [K02 NS080915, NS036630, 1UL1 RR024156-01, PO412196-G, NINDS R01 NS060113, NINDS R01 NS073872, NIA P50 AG 008702, NINDS NS36630, P50 NS038370]
  19. Parkinson's Disease Foundation (PDF)
  20. Smart Foundation
  21. PDF
  22. Instituto de Salud Carlos III
  23. Fondo de Investigaciones Sanitarias de la Seguridad Social
  24. National Institute for Occupational Safety and Health
  25. Department of Defense
  26. NIH
  27. California Institute for Regenerative Medicine
  28. Norwegian Parkinson Foundation
  29. Norwegian Research Council
  30. Netherlands Organization for Scientific Research (NWO-VIDI grant)
  31. Stichting Parkinson Fonds (the Netherlands)
  32. governmental funding for clinical research within the Swedish National Health Services (ALF-YF)
  33. Swedish Parkinson Foundation (Parkinsonfonden)
  34. Swedish Parkinson Academy (Parkinsonakademien)
  35. program Investissements d'avenir [ANR-10-IAIHU-06]
  36. French Agency for Research
  37. European Union
  38. NPF
  39. Pacific Alzheimer Research Foundation
  40. Canada Research Chairs program
  41. PSC
  42. NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024156] Funding Source: NIH RePORTER
  43. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073872, R01NS060113, K02NS080915, R56NS036630, U01NS052592, P50NS038370, P50NS072187, P50NS053488, R01NS078086, R01NS036630] Funding Source: NIH RePORTER
  44. NATIONAL INSTITUTE ON AGING [P30AG036468, P50AG008702, P01AG009215, U01AG029213, P30AG010124, P01AG017586, P01AG019724, U01AG024904] Funding Source: NIH RePORTER

Ask authors/readers for more resources

IMPORTANCE Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of genetic Parkinson disease (PD) known to date. The clinical features of manifesting LRRK2 mutation carriers are generally indistinguishable from those of patients with sporadic PD. However, some PD cases associated with LRRK2 mutations lack Lewy bodies (LBs), a neuropathological hallmark of PD. We investigated whether the presence or absence of LBs correlates with different clinical features in LRRK2-related PD. OBSERVATIONS We describe genetic, clinical, and neuropathological findings of 37 cases of LRRK2-related PD including 33 published and 4 unpublished cases through October 2013. Among the different mutations, the LRRK2 p.G2019S mutation was most frequently associated with LB pathology. Nonmotor features of cognitive impairment/dementia, anxiety, and orthostatic hypotension were correlated with the presence of LBs. In contrast, a primarily motor phenotype was associated with a lack of LBs. CONCLUSIONS AND RELEVANCE To our knowledge, this is the first report of clinicopathological correlations in a series of LRRK2-related PD cases. Findings from this selected group of patients with PD demonstrated that parkinsonian motor features can occur in the absence of LBs. However, LB pathology in LRRK2-related PD may be a marker for a broader parkinsonian symptom complex including cognitive impairment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available